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BACKGROUND: CC chemokine ligand (CCL)5 and its
receptor CCR5 contribute to leukocyte migration into
lungs of patients with diffuse lung diseases (DLD).
Pharmacological regulation of CCL5 and CCR5 ex-
pression was therefore explored in bronchoalveolar
cells obtained from patients with DLD.
Methods: Cells from 21 patients were co-cultivated in
vitro with tumour necrosis factor-a and dexametha-
sone, cyclosporin A (CyA) or pentoxifylline. Chemo-
kine mRNA expression and protein production was
assessed by reverse transcription-polymerase chain
reaction and enzyme-linked immunosorbent assay,
respectively.
Results: Dexamethasone altered CCL5 mRNA expres-
sion and suppressed its protein levels. CyA inhibited
chemokine mRNA expression but not protein pro-
duction. Pentoxifylline did not affected chemokine
expression. Both dexamethasone and CyA sup-
pressed CCR5 mRNA transcripts.
Conclusion: In conclusion, while dexamethasone
downregulates the CCL5 functional form, CyA and
pentoxifylline have no effects on CCL5 protein. These
data provide in vitro correlation for clinical applica-
tions of immunomodulators in therapy of DLD.
Key words: Dexamethasone, Cyclosporin A, Pentoxifyl-
line, Sarcoidosis, RANTES, Glucocorticoids, Bronchoalveo-
lar cells
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Introduction
Chemokines (chemotactic cytokines) are low mole-
cular weight proteins secreted by a variety of cells
including leukocytes, epithelial cells, endothelial
cells, fibroblasts and other cell types.
1 These factors
have been identified as attractants and activators of
different types of blood leukocytes to sites of infec-
tion and inflammation.
2 Acting via an array of G-
protein-coupled receptors, chemokines play an im-
portant role in the pathogenesis of numerous inflam-
matory diseases, including lung inflammatory
diseases, and also other immunopathologies.
3 5
Diffuse lung diseases (DLD) are characterised by
accumulation of inflammatory cells resulting in
pathological alveolar and interstitial inflammation.
The progressive derangement of alveolar architec-
ture, deposition of extracellular matrix components
and loss of functional tissue follow this process.
Activated leukocytes produce proteins with proin-
flammatory properties, among those chemokines.
These mediators cause further recruitment of inflam-
matory cells from the circulation into the lung.
6
The chemokine RANTES (regulated on activation,
normal T-cell expressed and secreted), CC chemo-
kine ligand (CCL) 5, is a CC chemokine originally
thought to be a T-cell-specific sequence.
7 Recently, a
number of cells have been found to express CCL5
including platelets, monocytes, B cells, natural killer
cells, epithelial cells, fibroblasts and endothelial
cells.
6 It has been demonstrated that CCL5 recruits
and activates not only T cells, but also other
leukocytes including basophils, eosinophils, mast
cells, dendritic cells, monocytes and B cells.
6,8 The
studies from our group and others
9 11 have provided
important information on the role of CCL5 and its
receptor CCR5 in the pathogenesis of DLD, especially
pulmonary sarcoidosis. These studies have demon-
strated that increased expression of CCL5 and CCR5
mRNA contributes to the accumulation of lympho-
cytes in diffuse lung diseases acting in concert with
other chemokines.
The glucocorticoids such as dexamethasone (Dx)
are used as the drugs of the first-line in the therapy of
DLD because of their anti-inflammatory and immu-
nomodulatory effects. Their effect is based on the
inhibition of transcription factor nuclear factor-kB.
12
This process affects the expression of chemokine
genes.
Besides corticosteroids, other more selective im-
munomodulatory drugs like cyclosporin A (CyA)
have been studied and clinically used in treatment
of DLD.
13 CyA blocks T-cell function after alloantigen
stimulation by inhibiting production of a number of
cytokines such as interleukin-2, tumour necrosis
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215factor-a (TNF-a) and granulocyte /macrophage col-
ony stimulating factor.
12 CyA has been already
clinically tested in the therapy of sarcoidosis, but
with contradictory results.
13
Recently, immunomodulatory and anti-inflamma-
tory properties of pentoxifylline (Px) have been
reported.
14 16 This xanthine derivative is primarily
used for the treatment of vascular diseases. However,
an inhibitory effect of Px on the levels of TNF-a was
demonstrated,
15 which stimulated its first clinical use
for the therapy of sarcoidosis.
17
The effect of the aforementioned drugs on chemo-
kine production has been studied before. However,
other cell types of patients with other disorders than
DLD were subjected to these modulators in vitro:f o r
example, the effect of Dx on bronchial and epithelial
cells of asthma patients was investigated.
18,19 So far
there has been little information about in vitro effect
of Dx, CyA and Px on population of bronchoalveolar
cells from the lung of patients with DLD. We wished
to verify whether the beneficial therapeutic effect of
immunomodulators on DLD is due to their inhibitory
effects on chemokine, especially CCL5, mRNA ex-
pression and subsequent protein release by bronch-
oalveolar cells. The chemokine CCL5 and its receptor
CCRS were chosen for these studies because of its
relevance for pathobiological mechanisms of DLD.
Materials and methods
Study population
Bronchoalveolar lavage was performed according to
our standard procedure
20 in 21 patients with DLD.
For diagnoses and laboratory characteristics, refer to
Table 1.
The study was performed with the approval of the
Ethics Committee of the Medical Faculty of Palacky
University Olomouc.
Cultivation of bronchoalveolar cells
The cells were isolated from bronchoalveolar fluid
and washed twice in RPMI-1640 medium (USOL,
Prague, Czech Republic). The recovered cells were
cultivated in the concentration 1 /10
6 cells in 1 ml of
RPMI-1640 medium with 8% of bovine serum (ZD,
Hustopece, Czech Republic), 100 U of Penicillin
(Leciva, Praque, Czech Republic), 100 mg of strepto-
mycin (Leciva) and 7.5% NaHCO3 (USOL). To in-
vestigate the effect of Dx, CyA and Px on chemokine
expression, the drugs were added 30 min before
TNF-a stimulation.
18 The concentrations of drugs and
of stimulator are presented in Table 2, where also
their manufacturers are specified. The cultivation was
performed at 378C and 5% CO2. After 21 h of
cultivation (culture duration determined in prelimin-
ary experiments), the supernatant was separated and
stored at  /808C for further analysis. The suspension
of cultured cells was centrifuged (250 /g, 8 min),
and the pellet was re-suspended in 1.5 ml of 0.1%
diethyl pyrocarbonate in phosphate-buffered saline
and centrifuged twice (250 /g, 8 min) for subse-
quent mRNA extraction.
mRNA extraction and reverse transcription
The final cell pellet was used to extract mRNA by
means of biomagnetic separation-Dynabeads (Dynal,
Oslo, Norway) as previously described.
21 Briefly, 9.0
ml of mRNA solution, obtained by biomagnetic
separation, were incubated with 2.0 ml of oligo(dT)15
(Promega, Southampton, UK) for 5 min at 958C, and
subsequently for 5 min at 48C. Reverse transcription
was performed at 428C for 60 min and the samples
were heated to 808C for 10 min to terminate the
reaction. Each reaction contained 9.0 ml of mRNA
solution, 2.0 ml of oligo(dT)15 primer (Promega),
5 mM of MgCl2 (Promega), 1 mM of each deoxynu-
cleotide triphosphate (Promega), 10 U of avian mye-
loblastosis virus reverse transcriptase (Promega) and
10 /20 U of RNAse inhibitor (Promega) in a total
volume of 18 ml. The resulting cDNA was diluted five-
fold in sterile water and stored at 48C.
Polymerase chain reaction
Polymerase chain reactions (PCRs) were performed
with oligonucleotide primers specific to CCL5, CCR5
and b-actin designed from the published cDNA
sequences.
11,22 The sequences of the primers were
as follows: 5?-TCA TTg CTA CTg CCC TCT gC (CCL5
sense) and 5?-CCTAgC TCATCT CCA AAg Ag (CCL5
antisense), 5?-gAT ggA TTA TCA AgT gTC AAg
Table 1. Clinical and laboratory data of 21 investigated
subjects with DLD
Age (years) 46 (25 /69)
Sex
Male 6
Female 15
Smoking
Smokers 4
Non-smokers 13
Ex-smokers 4
BALF cell concentration (10
5/ml) 2.6 (0.4 /4.6)
BALF differential count
% Macrophages 83.0 (24.0 /97.0)
% Lymphocytes 17.0 (0.0 /63.0)
% Neutrophils 0.3 (0.0 /37.0)
% Eosinophils 0.0 (0.0 /34.0)
% Basophils 0.0 (0.0 /0.0)
BALF CD4
 /CD8
  T-cell ratio 1.8 (0.5 /16.1)
Data presented as median values (range, minimum /maximum).
BALF, bronchoalveolar lavage fluid.
Diagnosis: sarcoidosis (n /11), cryptogenic fibrosing alveolitis (n /
3), lymphocyte alveolitis (n /2), interstitial pneumonia (n /2),
extrinsic allergic alveolitis (n /2), DLD after Cordarone (n /1).
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C (CCR5 antisense), and 5?-TCC TgT ggC ATC CAC
gAA ACT (b-actin sense) and 5?-gAA gCA TTT gCg
gTg gAC gAT (b-actin antisense). The predicted sizes
of the amplified CCL5 and CCR5 cDNA products were
243 and 91 base pairs (bp), respectively; the size of
the b-actin amplicon was 315 bp. The PCR reaction
mix contained the sense and antisense primers (0.25
mM each), deoxynucleotide triphosphates (0.2 mM
each; Promega), 1.5 mM of MgCl2 (Promega), 1.25 ml
of PCR buffer 10x (Promega), 5 ml of cDNA and 0.5 U
of Taq polymerase (Promega) in a total reaction
volume of 13 ml. After initial denaturation (5 min at
958C), 36 cycles for CCL5 and 32 cycles for b-actin
were performed using MJR-Tetrad thermocycler
(MJR, Waltham, MA, USA). The optimal number of
amplification cycles for each gene was defined in
order to reach the exponential phase of the amplifi-
cation process.
22 One cycle consisted of denaturation
(958C, 45 sec), annealing (558C, 45 sec) and exten-
sion (728C, 90 sec). The final extension (728C,
10 min) was carried out and the reaction was
terminated by chilling to 48C. A negative control
reaction containing all components except template
cDNA was set up with every PCR experiment. All
determinations were performed in duplicate.
Identification of PCR products, measurement
and semi-quantification of CCL5 and CCR5
mRNA expression
The amplification products were separated on 2%
agarose gel (Agarose; Serva, Heidelberg, Germany)
stained by ethidium bromide (Sigma, St Louis, MO,
USA). The negative images of the gels on Polaroid
type 665 film (Polaroid Corp., Cambridge, MA, USA)
were scanned on a laser densitometer and the optical
density (OD) values for the individual products were
obtained (Image Master software; Pharmacia, Stock-
holm, Sweden). CCL5 (CCR5) mRNA expression was
semi-quantified by normalising CCL5 expression to b-
actin. The chemokine/b-actin optical density ratios
(ODRs) were derived for each subject as previously
described
22 (ODR /OD CCL5/OD b-actin for CCL5,
or OD CCR5/OD b-actin for CCR5).
Quantification of CCL5 protein production by
enzyme-linked immunosorbent assay
The concentration of immunoreactive CCL5 protein
in cell culture supernatant was measured using
commercially available solid-phase sandwich en-
zyme-linked immunosorbent assay (ELISA) (Quanti-
kine ELISA assay; R&D Systems, Abingdon, UK).
Briefly, 100 ml duplicates of cell culture supernatant
or standard (recombinant human CCL5) were applied
to wells of an ELISA tray pre-coated with a mouse
monoclonal anti-human CCL5 antibody. After incu-
bation (2 h, room temperature), the wells were
washed three times before addition of a horseradish
peroxidase-conjugated goat-polyclonal anti-CCL5
antibody. Trays were incubated (1 h, room tempera-
ture), washed and then chromogen and substrate
solution (tetramethylbenzidine and hydrogen perox-
ide) was added. After incubation (20 min, room
temperature), reactions were stopped by the addition
of 2 M of sulfuric acid and absorbance was measured
at 450 nm using an ELISA-plate reader (Titertek
Multiskan MCC/340; Labsystems, Vantaa, Finland).
The data were processed by KIM-E software (USOL).
The lower limit for the detection of CCL5 was 19.0
pg/ml.
Statistical analysis
The effect of studied drugs on CCL5 and CCR5 mRNA
expression and CCL5 protein production is expressed
as an index of modulation, which normalises the data
to the TNF-a stimulated values for mRNA and protein
expression in cultures treated by studied drugs.
A paired t-test was employed to investigate differ-
ences in chemokine mRNA expression and protein
production in modulated cell cultures in vitro. pB/
0.05 was considered statistically significant.
Results
To explore the effect of immunomodulators on CCL5
in DLD, bronchoalveolar cells were co-cultivated in
vitro with TNF-a and Dx, CyA or Px. The results are
summarised in Table 3.
Table 2. Concentrations of drugs and number of evaluated cultures inﬂuenced by particular drugs
Drug Concentration/ml of culture
a Producer Number of
cultures
b
mRNA Protein
TNF-a 10 ng
18 National Institute for Biological Standards, Potters Bar, UK 16 15
Dexamethasone 0.43 mg
18 Sigma, St Louis, MO, USA 14 14
Cyclosporin A 10 ng
26 Sandoz, Basel, Switzerland 9 6
Pentoxifylline 20 mg
16 Biotika, Slovenska Lupca, Slovakia 4 6
a Reference citations from which the in vitro dosage was adopted are included.
b Number of cultures available for studies of modulatory effect of particular drug.
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scripts (Fig. 1) and especially on its protein release:
CLL5 protein concentrations were downregulated in
13 from 14 (93%) cultures treated by Dx (pB/0.01).
TNF-a-induced transcripts were reduced by Dx;
however, the difference did not attain significance.
The suppression of CCL5 by CyA was observed on
the mRNA level (p /0.02). By contrast, CyA had
virtually no effect on the level of CCL5 protein in cell
culture supernatant. Px did not influence the expres-
sion and release of the CCL5 chemokine from
bronchoalveolar cells; a uniform pattern was ob-
served in the majority of in vitro experiments with
this drug.
When subanalysis was performed with the data
obtained in bronchoalveolar cells from the patients
with sarcoidosis, the pattern of modulation of che-
mokine expression and production by all three
investigated drugs was nearly identical to that in the
DLD group as a whole: Dx suppressed TNF-a-
induced expression of CCL5 protein in bronchoal-
veolar cells of 9/10 (90%) patients with sarcoidosis
(Fig. 2).
Modulation of TNF-a-induced CCR5 mRNA expres-
sion was investigated in a subset of patients. CCR5
transcripts were downregulated in six of seven (86%)
cultures treated by Dx and in five of six (83%)
cultures in the presence of CyA (Dx, p /0.02; CyA,
p /0.04; Table 3).
Discussion
In this study, we were interested how three drugs
used or tested in the therapy of DLD, namely Dx, CyA
and Px, modulate expression of CCL5 (RANTES),
which has been implicated in pathogenesis of DLD.
We studied their effect on TNF-a-induced expression
of CCL5 mRNA and release of CCL5 protein by
bronchoalveolar lavage fluid cells from patients
with DLD in vitro. We also explored whether Dx
and CyA modulate expression of mRNA for the
RANTES receptor, CCR5.
The concentration of all studied drugs was selected
to correspond to therapeutic levels in vivo.W e
observed that 10
 6 M of Dx, the drug of first-line in
the therapy of DLD, inhibited TNF-a-induced CCL5
mRNA expression and especially protein release by
bronchoalveolar cells. It has been previously re-
ported that CCL5 plays an important role in the
pathogenesis of sarcoidosis
9 and also of other DLD.
10
Our current findings indicate that the beneficial effect
of Dx in the therapy of DLD can be explained by
suppression of expression CCL5 mRNA and namely
protein production. From general point of view, our
observations also correspond to the results of Kwon
et al.,
18 who described a suppressive effect of Dx on
CCL5 mRNA and protein in lung epithelial cells.
By contrast to Dx, CyA was able to effectively
downregulate CCL5 at the transcript but not at
protein level. The discrepancy between significant
reduction of chemokine mRNA expression by CyA
and virtually no effect of this immunosupressive on
Table 3. Effects of Dx, CyA and Px on TNF-a-induced CCL5 and CCR5 mRNA expression and CCL5 protein production in
bronchoalveolar cell from patients with DLD
Drug Mean Standard error of the mean p value Mean Standard error of the mean p value
CCL5 mRNA CCL5 protein
Dexamethasone 0.80 0.11 0.09 0.71 0.04 B/ 0.01
Cyclosporin A 0.75 0.09 0.02 0.97 0.06 0.69
Pentoxifylline 1.06 0.16 0.80 1.00 0.07 1.00
CCR5 mRNA CCR5 protein
Dexamethasone 0.78 0.07 0.02 Not evaluated
Cyclosporin A 0.65 0.12 0.04 Not evaluated
The modulatory effect is expressed as the index of modulation; for details, see methods.
FIG. 1. The effect of Dx on the TNF-a-induced expression of
CCL5 mRNA in bronchoalveolar cells (a representative
example). The products of CCL5-speciﬁc PCR are shown in
lanes 5 /7 (lane 5, non-stimulated culture; lane 6, TNF-a-
stimulated culture; lane 7, culture co-stimulated with TNF-a
and Dx). Beta-actin amplicons in lanes 1 /3 documents that
equal amounts of RNA were extracted from the cultures (in
the same order from left to right). Lane 4, molecular weight
markers (PCR marker; Promega); bands are from the top
1000 /750 /500 /300 /150 /50 bp.
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veolar cells in vitro fits with the unsuccessful out-
come of clinical experiments in the therapy of
sarcoidosis */ the most frequent and representative
DLD.
13 A possible explanation for the inability of CyA
to alter CCL5 protein production in both in vitro and
in vivo settings is its more selective action directed
mainly at activated T lymphocytes.
11 However, there
are not only lymphocytes, but also alveolar macro-
phages and granulocytes in the bronchoalveolar
space of patients with DLD, and these may not be
influenced by CyA. By contrast, the effect of gluco-
corticoids is more complex, and includes several
types of immune cells.
23 Alternatively, the observed
discrepancy between effects of CyA on CCL5 mRNA
and protein levels can also be due to possible effects
of post-transcriptional and post-translational regula-
tion mechanisms including release and metabolism of
CCL5 protein.
24
The immunomodulatory properties of the third
studied drug, Px, have been described recently. Its
immunomodulatory mechanism is based on the
inhibition of TNF-a production.
15,16 In this study,
neither CCL5 mRNA nor protein was altered in the
cultures influenced by Px (20 mg/ml of culture). The
data suggest that Px has not a direct influence on
expression and protein release of chemokine CCL5 in
vitro. Px was, however, successfully used for treat-
ment of patients with progressing sarcoidosis.
17 It is,
therefore, possible that Px beneficial effects are
limited either to subgroup of patients with active
disease that were under-represented in our study
group, or that this drug targets different pathogenetic
mechanisms than cellular influx regulated by chemo-
kines.
We are aware of the heterogeneity of the group of
DLD, which were represented in our study. However,
we tried to ensure that the composition of our group
reflects real frequencies of individual DLD, with
sarcoidosis and cryptogenic fibrosing alveolitis
(CFA) as their most common representatives. In this
regard it should be mentioned that the pattern of
modulation of CCL5 production by bronchoalveolar
cells was virtually identical when subanalysis was
performed for sarcoidosis. This is important in the
context of participation of CCL5 and of its receptor,
CCR5, in the pathogenesis of this representative
DLD.
11 In this regard we would like to mention that
analysis of the CCR5 mRNA expression showed
downregulation of CCR5 transcripts by Dx and CyA.
To our knowledge, this is the first report of a
suppressive effect of these drugs on CCR5 expres-
sion.
In summary, our findings suggest that, among the
three studied drugs, Dx is the most effective inhibitor
of CCL5 chemokine production in the bronchoalveo-
lar space of patients with DLD. This drug not only
suppresses TNF-a-induced CCL5 protein release from
bronchoalveolar cells, but also downregulates ex-
pression of mRNA for its receptor, CCR5. The data
presented in this study, therefore, supports the use of
corticosteroids in the therapy of DLD. This concept
has been further supported by our recent observa-
tions of dexamethasone’s suppressive effect on
CCL19 (MIP-3beta), a recently described mediator
of lymphocyte alveolitis in sarcoidosis.
25
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